Opticyte

Executive Summary

Opticyte is a San Diego-based medical device company founded in 2018, focused on developing the VitalO₂, the first non-invasive device capable of measuring intracellular oxygen levels in real-time, complementing traditional blood oxygen saturation monitoring. The company's mission is to enable early detection of critical conditions such as sepsis and organ failure, while addressing healthcare inequities by providing accurate readings across all skin tones—a known limitation of conventional pulse oximeters. With a strong emphasis on patient safety and equitable care, Opticyte's technology has the potential to transform critical care monitoring by offering clinicians a direct window into tissue oxygenation, which could lead to earlier interventions and improved outcomes. The company is currently in the development stage, with its technology poised to address a significant unmet need in the medical device market. Opticyte's progress to date includes the conceptualization and early-stage development of the VitalO₂ device, though it has not yet initiated clinical trials or secured regulatory approvals. The company's focus on cellular oxygen measurement positions it at the forefront of a novel diagnostic paradigm, but it remains at an early stage of commercialization. Future success will depend on successful clinical validation, regulatory clearance, and adoption in critical care settings. The company's unique value proposition in health equity and early detection gives it a competitive edge, but execution risks and the need for substantial capital investment remain.

Upcoming Catalysts (preview)

• Q3 2026FDA Pre-Submission or Breakthrough Device Designation30% success
• Q4 2026Initial Clinical Feasibility Study Results25% success
• Q2 2026Series A Funding Round Closure40% success